Core Insights - The National Medical Insurance Administration (NMIA) has announced several measures and data at the National Medical Security Work Conference, highlighting improvements in medical insurance coverage and support for healthcare institutions. Group 1: Medical Insurance Coverage - The total amount of personal accounts for employee medical insurance has exceeded 100 billion yuan, with over 7.8 billion instances of account sharing in the past five years [2] - A comprehensive outpatient medication guarantee mechanism for hypertension and diabetes has been established, benefiting over 340 million people through major illness insurance [2] - Medical assistance has reached 1.189 billion people, with over 90% reimbursement for rural disadvantaged groups [2] Group 2: Support for Healthcare Institutions - By 2025, the NMIA will implement a comprehensive payment reform based on disease categories, with a 2.0 version of the payment scheme to be introduced [3] - All medical insurance areas will conduct real-time settlements, reducing the payment timeline to within 20 working days after submission, with some areas achieving next-day settlements [3] - The NMIA plans to release a 3.0 version of the payment scheme by 2026, promoting the use of new drugs and technologies in clinical settings [3] Group 3: Maternity and Long-term Care Insurance - The NMIA aims to achieve "no out-of-pocket" expenses for childbirth within policy coverage by 2026, expanding maternity insurance to cover flexible employment and migrant workers [4] - The long-term care insurance system is being developed to cover approximately 300 million insured individuals, benefiting over 3.3 million disabled individuals [4] - Nearly 95% of insurance areas will directly distribute maternity benefits to insured individuals [4] Group 4: Anti-fraud Measures - Over the past five years, approximately 120 billion yuan has been recovered from fraudulent medical insurance claims, with comprehensive coverage of inspections across all provinces [5] - The NMIA has utilized big data models and intelligent regulatory systems to recover 9.5 billion yuan in fund losses [5] - In 2026, the NMIA will enhance inspection efforts, focusing on areas with high out-of-pocket rates and ensuring strict penalties for fraudulent activities [6]

Group 1 - The core viewpoint of the article highlights that the Central Economic Work Conference proposed policies to optimize drug procurement and deepen medical insurance payment reforms, which are expected to boost domestic demand in the pharmaceutical industry and signal a shift towards high-quality development for Chinese pharmaceutical companies [1] - The optimization of drug centralized procurement is aligned with the principle of "anti-involution," aiming to stabilize production and achieve a sustainable balance between affordable pricing and reliable quality in clinical medications [1] - The introduction of a "dual directory" mechanism for medical insurance payment reform is expected to facilitate the inclusion of high-value innovative drugs that are not covered by basic medical insurance, thus supporting innovation while ensuring basic healthcare needs are met [2] Group 2 - The establishment of a national long-term care insurance service project directory is anticipated to standardize long-term care services, enhance service quality, and stabilize the rights of beneficiaries, contributing to the smooth operation of long-term care insurance funds [3]

Core Viewpoint - The Central Economic Work Conference held in Beijing on December 10-11 outlined key tasks for economic work in the coming year, including optimizing drug centralized procurement and deepening medical insurance payment reform [1]. Group 1: Drug Centralized Procurement - Since the launch of the "4+7" centralized procurement pilot by the National Healthcare Security Administration (NHSA) in November 2018, eleven batches of drug procurement have been conducted, successfully procuring 490 types of drugs [1]. - The goals of drug centralized procurement include reducing the economic burden on insured individuals, improving the efficiency of medical insurance fund usage, and encouraging companies to transition towards innovation [1]. - The eleventh batch of centralized procurement, which produced results on October 27, 2025, included 55 types of drugs covering common medications in various fields such as anti-infection, anti-allergy, anti-tumor, and blood sugar regulation [1]. Group 2: Optimization of Procurement Rules - The eleventh batch of procurement achieved its expected goals of "stabilizing clinical use, ensuring quality, countering excessive competition, and preventing collusion" by aligning selected products with medical institution needs, raising qualification thresholds for bidding companies, and guiding rational pricing [1]. - There is ongoing attention on how to further counter excessive competition in future drug procurements, with suggestions for establishing a minimum bidding price to provide more certainty for companies [2]. - Experts suggest that procurement rules could be further strengthened around the four dimensions of "stabilizing clinical use, ensuring quality, countering excessive competition, and preventing collusion," including potentially setting a "bottom price" for bids [2].

Group 1 - The core focus of the Central Economic Work Conference held on December 10-11 in Beijing is to enhance efforts in anti-involution, including optimizing drug centralized procurement and deepening medical insurance payment reform [1] - Since the launch of the "4+7" centralized procurement pilot by the National Healthcare Security Administration in November 2018, eleven batches of drug procurement have been conducted, successfully procuring 490 types of drugs [1] - The goals of drug procurement include reducing the economic burden on insured individuals by cutting out intermediaries and improving the efficiency of medical insurance fund usage, while also pushing companies towards innovation [1] Group 2 - The eleventh batch of national drug centralized procurement, which concluded on October 27, 2025, included 55 types of drugs across various common therapeutic areas, achieving the expected goals of "stabilizing clinical use, ensuring quality, countering involution, and preventing collusion" [2] - The procurement process has been optimized to better match selected products with medical institution needs, raise the qualification thresholds for bidding companies, encourage rational pricing, and standardize bidding behavior [2] - There is ongoing high interest in how to further counter involution in future drug procurements, with suggestions for establishing a minimum bidding price to provide more certainty for companies [3] Group 3 - Experts suggest that the procurement rules can be further strengthened around the four dimensions of "stabilizing clinical use, ensuring quality, countering involution, and preventing collusion," including potentially setting a minimum price for selected drugs [3] - There is a proposal to explore separating medical insurance payment standards from drug prices, allowing for a situation where non-selected drugs could be priced above the insurance payment standard, ensuring the availability of off-patent original drugs while requiring lower prices for non-selected options [3]

Core Points - The Central Economic Work Conference was held in Beijing on December 10-11, focusing on key tasks for economic work in the coming year [1] - Emphasis on prioritizing people's livelihoods and addressing practical issues for the public [1] Employment and Labor - Implementation of actions to stabilize and expand employment, particularly for key groups such as college graduates and migrant workers [1] - Encouragement of flexible employment and new employment forms to participate in employee insurance [1] Education - Adjustment of educational resource allocation to increase the supply of ordinary high school places and enhance undergraduate admissions at quality universities [1] Healthcare - Optimization of centralized drug procurement and deepening reforms in medical insurance payment methods [1] - Implementation of rehabilitation and nursing expansion projects, along with the promotion of long-term care insurance systems [1] Social Welfare - Strengthening support for vulnerable groups and advocating for a positive view on marriage and childbirth to stabilize the newborn population [1] Safety and Security - Commitment to ensuring safety in production, disaster prevention and relief, and food and drug safety [1]

Core Insights - The company reported a 4 percentage point decrease in drug cost ratio for its hospitals in the first three quarters, now standing at 36% [2] - Despite the reduction in drug cost ratio, the supply chain profit margin remained stable year-on-year [2] - The company has actively responded to the reform of medical insurance payment methods, leading to a 3 percentage point increase in effective revenue ratio during the same period [2]

Financial Performance - In the first half of 2025, the company achieved a revenue of 1.588 billion CNY, a year-on-year decrease of 20.63% [2] - The medical services segment generated 1.38 billion CNY, while the pharmaceutical segment contributed 210 million CNY [2] - Gross margin was 28.2%, with the medical services segment at 26% and the pharmaceutical segment at 40.47% [2] - Pre-tax operating profit was 33.73 million CNY, and net profit attributable to shareholders was 7.43 million CNY [2] - Operating cash flow was 140 million CNY, a decline of 15% [2] Cost Management - The drug cost ratio was 24.10%, down 2.29 percentage points year-on-year [4] - The cost of consumables accounted for 12.81%, a decrease of 0.91 percentage points [4] - Labor costs represented 36.24%, an increase of 0.71 percentage points, but variable labor costs decreased [4] - Overall, variable cost ratios are declining, indicating effective cost control [4] Hospital Operations - In the first half of 2025, outpatient visits and average outpatient costs remained stable, while inpatient visits decreased by approximately 9% and average inpatient costs fell by about 12% [2] - The company aims to control the drug cost ratio to around 35% in the second half of 2025 [5] - As of mid-2025, the proportion of procurement from centralized purchasing in drug costs was about 23% [6] Insurance and Revenue - Insurance revenue accounted for approximately 50.5% of total revenue in the first half of 2025 [7] - The payment cycle for insurance is typically 1-2 months for monthly payments and annual settlements for yearly payments [8] Strategic Developments - The company is focusing on enhancing hospital standards and technical capabilities, with 42 key disciplines and specialties established [16] - The company is actively adapting to policy changes in medical insurance and drug procurement, aiming to improve management and operational efficiency [15][17] - Plans for bed expansion include 800 new beds at Siyang Hospital and additional projects at other facilities [13][12] Future Outlook - The company anticipates a slowdown in revenue growth due to ongoing reforms in medical insurance payment methods, but expects to enhance management and service capabilities [15] - The focus will remain on integrating medical and pharmaceutical services, as well as expanding non-insurance revenue projects [17]

Core Points - The article discusses the implementation of a new payment reform in China's healthcare system, focusing on a disease-based payment model to improve efficiency and reduce excessive medical practices [1][2] - The National Healthcare Security Administration (NHSA) has issued interim measures to establish a dynamic adjustment mechanism for disease grouping schemes, aiming for adjustments every two years [1][2] Summary by Sections Payment Reform Overview - The traditional payment method in China's healthcare system is based on itemized billing, which can lead to over-treatment and unnecessary medical procedures [1] - Since 2019, the NHSA has been piloting the disease-based payment model, which groups patients by similar conditions and sets a standard payment based on historical data [1] Implementation and Challenges - After six years, the disease-based payment model has expanded from pilot programs to a nationwide implementation, covering all coordinated areas and improving the efficiency of healthcare fund usage [1] - Challenges remain, including insufficient expectations for dynamic adjustments, uneven development of supporting measures across regions, and varying levels of management capabilities [1] New Measures and Goals - The new measures aim for a standardized framework focusing on total budget management, grouping schemes, and core elements [2] - The NHSA emphasizes the importance of a rigid total budget and collaborative development of grouping schemes with healthcare institutions [2] - The introduction of these measures marks a shift from "scale expansion" to "precise regulation," aiming to reduce regional management disparities and enhance the role of healthcare institutions in the payment reform process [2]

Core Viewpoint - The article discusses the implementation of a new payment reform in China's healthcare system, focusing on a disease-based payment model to enhance efficiency and control costs in medical services [1][2]. Summary by Sections Payment Reform Overview - The National Healthcare Security Administration (NHSA) has introduced the "Interim Measures for the Management of Disease-Based Payment" to promote a multi-faceted payment reform primarily based on disease categories [1]. - The new measures will establish a dynamic adjustment mechanism for disease grouping schemes, with adjustments occurring approximately every two years [1][2]. Disease-Based Payment Mechanism - Disease-based payment involves grouping diseases or calculating values to implement a "bundled payment" system for medical institutions [2]. - The NHSA has been actively promoting disease-based payment for inpatient medical expenses, focusing on two pilot projects: Diagnosis-Related Groups (DRG) and Disease-Based Value Payment (DIP) [2]. - Adjustments to the DRG grouping scheme will maintain stability in major diagnostic categories while focusing on core and detailed subgroup adjustments [2]. Key Policies and Measures - The new measures clarify policies, key technologies, core elements, and supporting measures related to disease-based payment, emphasizing rigid total budget management [2]. - The NHSA will incorporate disease-based payment requirements into agreement management, enhance monitoring and evaluation of reform effectiveness, and strengthen fund supervision [2]. Special Case Mechanism - A "special case negotiation" mechanism has been established to support medical institutions in treating complex and severe patients, allowing for reasonable use of new drugs and technologies [3]. - Cases eligible for special negotiation include those with long hospital stays, high resource consumption, and complex conditions that do not fit standard payment models [3]. Impact on Medical Institutions - The shift from fee-for-service to disease-based payment encourages medical institutions to control costs while still generating revenue [5]. - Institutions can apply for special case negotiations for patients requiring extensive resources or new treatments, ensuring adequate care [5]. Impact on Patients - The reform does not alter the patient discharge settlement experience, and patients may see a reduction in out-of-pocket expenses due to fewer unnecessary medical services [6]. - The NHSA has not imposed restrictions on hospital stays, and any coercive practices by medical institutions regarding discharge will be strictly addressed [6].

Core Viewpoint - The National Healthcare Security Administration (NHSA) has officially issued the "Interim Measures for the Management of Disease-Specific Payment in Medical Insurance," aiming to reform the payment system primarily based on disease categories, establishing a dynamic adjustment mechanism for disease grouping schemes every two years [1] Summary by Relevant Sections Payment Reform - The new payment method involves grouping diseases or calculating scores to implement "bundled payments" to medical institutions, requiring dynamic adjustments to adapt to clinical changes due to rapid advancements in medical technology [1] - The NHSA has been promoting disease-specific payment for inpatient medical expenses, conducting pilot programs for Diagnosis-Related Groups (DRG) and Disease-Specific Payment (DIP) [1][5] Key Policies and Mechanisms - The "Interim Measures" clarify policies, key technologies, core elements, and supporting measures related to disease-specific payments, emphasizing rigid total budget management and the need for reasonable expenditure budgeting [1] - The measures also incorporate requirements for disease-specific payments into agreement management, enhance monitoring and evaluation of reform effectiveness, and strengthen fund supervision [1] Special Case Payment Mechanism - A dedicated section in the measures supports medical institutions in treating complex and severe patients, allowing for a "special case single negotiation" mechanism for cases that are not suitable for standard disease payment [2][5] - Cases eligible for special negotiation include those with long hospital stays, high resource consumption, and the use of new drugs or technologies [2] Impact on Patients and Institutions - The shift from itemized payments to disease-specific payments aims to reduce unnecessary medical services, potentially lowering the out-of-pocket expenses for patients [6] - The NHSA has stated that there are no restrictions on hospital stays, and any coercive practices by medical institutions to discharge patients prematurely will be strictly addressed [6]